Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiome prediction of response and toxicity during durvalumab after chemoradiotherapy in locally advanced NSCLC
NL-OMON50946Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Leiden University Medical Center. Primary endpoints: Predictive value of microbiome for relapse at 6 months, Disease progression and 1 more. Started Jun 2022; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50946.